HopeStage
Back to all studies
Active Not RecruitingNCT05774665

Omega-3 added to depression care and inflammation markers

About this titleRead the official source — NCT05774665
Medication studyAges 18–65United States
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 65 years.

Listed locations
Atlanta and 2 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: January 30, 2025
Recruitment status
Active Not Recruiting
Enrollment listed in the registry
14
Sponsor
Massachusetts General Hospital
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug, Other
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT05774665
Official title
Show the full official title

Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression

Recruitment & locations

Not recruiting

Atlanta · Boston · Salt Lake City

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.

Does this study involve medication?

Yes. The study involves medication, including Omega 3.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as active, but no longer recruiting.

Want to explore more studies?

Explore studies